Pulse Biosciences, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Pulse Biosciences, Inc. (PLSE) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $40.55 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-10.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2022-11-10
- Pulse Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was -$15.94M, a 133.61% decline year-over-year.
- Pulse Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $47.42M, a 4813.99% increase year-over-year.
- Pulse Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2020-03-31 was $965.00K.
- Pulse Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2019-03-31 was -$42.57M.
- Pulse Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $16.15M, a 190.28% increase from fiscal 2020.
- Pulse Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $5.56M.
- Pulse Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2019 was -$44.20M, a 192.64% decline from fiscal 2018.
- Pulse Biosciences, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2018 was $47.72M, a 3579.03% increase from fiscal 2017.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-09-30 | $40.55M 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | -$13.82M 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | -$15.94M 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | $16.15M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $29.53M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $34.96M 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $47.42M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | $5.56M 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $171.00K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $30.87M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $965.00K 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$44.20M 10-K · filed 2022-03-31 | |||
| 2019-09-30 | -$41.53M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | -$40.32M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$42.57M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $47.72M 10-K · filed 2021-03-12 | |||
| 2018-09-30 | $2.94M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $3.41M 10-Q · filed 2019-08-08 | |||
| 2017-12-31 | $1.30M 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iRhythm Holdings, Inc. (IRTC) | United States | $3.651B | -281.06 |
| ICU MEDICAL INC/DE (ICUI) | United States | $4.153B | 18.85 |
| Heartflow, Inc. (HTFL) | United States | $4.225B | |
| AtriCure, Inc. (ATRC) | United States | $3.089B | |
| HAEMONETICS CORP (HAE) | United States | $4.821B | 36.52 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 |